RE: Further contracts soon1 Oct 2025 08:26
Dr Peter Sargent, CEO of Physiomics, commented:
"Following our strategic review early in 2024, the Company has made significant progress across its key growth initiatives. Changes and investments made initially resulted in record levels of contract wins in the year ended 31 June 2024 and I'm delighted to report that this momentum has been maintained in the year ended 30 June 2025 with total income growth of 46% year-on-year. Off the back of this, we're starting the current financial year ending 30 June 2026 with a record level of contracted projects, a new biometrics service-line already generating revenue, and real progress across our personalised medicine dosing software initiative."